Jay R. Venkatesan
Board Member
Elicio Therapeutics, Inc. (ELTX)Equibles does not estimate personal net worth.
Get an email with a short summary when Elicio Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ELTX alertsAbout Jay R. Venkatesan
Jay R. Venkatesan is recorded as Board Member at Elicio Therapeutics, Inc. (ELTX). The newest filing on record that lists Jay R. Venkatesan as Board Member at Elicio Therapeutics, Inc. (ELTX) is dated October 9, 2026. Jay R. Venkatesan was last confirmed as Board Member at Exicure, Inc. (XCUR) in a filing dated April 21, 2020. Elicio Therapeutics, Inc. reported in an 8-K filed June 2, 2023 that Jay R. Venkatesan was appointed Class III Director, effective June 1, 2023. The proxy statement of Elicio Therapeutics, Inc. reports total compensation of $2,429,275 for Jay R. Venkatesan in fiscal 2023, including a base salary of $243,944. Disclosed compensation is on record for 4 fiscal years. Elicio Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Elicio Therapeutics, Inc. includes Robert Connelly (CEO, Chief Accounting Officer and Board Member), Julian Adams (Chairman), Julian Adams, Ph.D. (Chairman and Board Member) and 7 others.
“Jay R. Venkatesan, M.D. and Carol Ashe being appointed as Class III directors of the Company whose terms expire at the Company's 2026 annual meeting of stockholders”
Affiliation history
-
Current
Start not stated–present
Last confirmed October 9, 2026
-
Start not stated–2022-04-27
Last confirmed by a filing; no departure on record
-
Start not stated–2020-04-21
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Elicio Therapeutics, Inc.
- Robert Connelly CEO, Chief Accounting Officer, Board Member
- Julian Adams Chairman
- Julian Adams, Ph.D. Chairman, Board Member
- Brian Piekos CFO
- Preetam Shah, Ph.D., M.B.A. CFO, Chief Accounting Officer
- Jennifer J. Rhodes General Counsel
- Allen R. Nissenson Board Member
- Allen R. Nissenson, M.D. Board Member
- Assaf Segal Board Member
- Carol Ashe Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Elicio Therapeutics, Inc. (ELTX) | former Chief Executive Officer, President, and Chairman of the Angion Board | $243,944 | $2,429,275 |
| 2022 | Elicio Therapeutics, Inc. (ELTX) | former Chief Executive Officer, President, and Chairman of the Angion Board | $608,000 | $1,518,849 |
| 2021 | Elicio Therapeutics, Inc. (ELTX) | M.D., President and Chief Executive Officer and Chairman of the Board | $587,100 | $2,539,199 |
| 2020 | Elicio Therapeutics, Inc. (ELTX) | M.D., President and Chief Executive Officer and Chairman of the Board | $570,000 | $1,394,398 |